Aclarion Secures U.S. Patent for AI-Driven Chronic Low Back Pain Assessment Platform

Aclarion, Inc., a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled "System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain," covering its machine learning-based platform for analyzing magnetic resonance spectroscopy data. The patent strengthens Aclarion's ability to scale by protecting its use of artificial intelligence in future versions of its Nociscan platform to automate biomarker identification, accelerate report generation, and reduce manual quality reviews. This development expands the company's intellectual property portfolio to 64 issued and pending patents worldwide, strengthening its long-term competitive position in the chronic low back pain market.

The newly issued patent covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. Importantly, the patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability enables consistent, reproducible outputs across imaging systems and sites, representing a key step toward broader clinical adoption. According to Brent Ness, Chief Executive Officer of Aclarion, "This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice."

The patent's implications are significant for addressing chronic low back pain, which affects approximately 266 million people worldwide. Aclarion's cloud-based Nociscan platform converts complex MRS spectral data into clinically actionable insights to help physicians distinguish between painful and non-painful discs in the spine. Clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. The patent protection enables Aclarion to build a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.

The patent issuance underscores Aclarion's strategy to build a differentiated, software-driven platform in the large and underserved chronic low back pain market. By combining proprietary signal processing with machine learning, the company is creating a system that provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information on Nociscan, readers can visit https://www.aclarion.com. The latest news and updates relating to Aclarion are available in the company's newsroom at https://tinyurl.com/aconnewsroom.